News
SHPH
1.750
+2.94%
0.050
Shuttle Pharmaceuticals Expands Phase 2 Clinical Trial Of Ropidoxuridine For Glioblastoma Treatment To Two Additional Sites, Bringing Total To Four Ready For Patient Enrollment
Benzinga · 6h ago
SHUTTLE PHARMACEUTICALS HOLDINGS INC - PHARMA ADDS TWO SITES FOR PHASE 2 TRIAL OF ROPIDOXURIDINE
Reuters · 6h ago
SHUTTLE PHARMA EXPANDS CLINICAL TRIAL SITE ENROLLMENT FOR PHASE 2 OF ROPIDOXURIDINE FOR TREATMENT OF PATIENTS WITH GLIOBLASTOMA
Reuters · 6h ago
Weekly Report: what happened at SHPH last week (0909-0913)?
Weekly Report · 8h ago
Weekly Report: what happened at SHPH last week (0902-0906)?
Weekly Report · 09/09 11:36
Why Shuttle Pharmaceuticals (SHPH) Is Extremely Volatile Today
Benzinga · 09/05 15:18
Shuttle Pharma Issued U.S. Patent For Selective Histone Deacetylase Inhibitors For Treatment Of Human Disease
Benzinga · 09/05 13:05
SHUTTLE PHARMA ANNOUNCES ISSUANCE OF U.S. PATENT FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE
Reuters · 09/05 13:00
Why Modular Medical Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
Benzinga · 09/05 09:33
Shuttle Pharmaceuticals Files Delayed Financial Statements, Reports Progress on Drug Study
Dow Jones · 09/04 21:38
SHUTTLE PHARMA PROVIDES SECOND QUARTER 2024 CORPORATE UPDATE
Reuters · 09/04 20:15
US Stocks Mixed; Trade Gap Widens In July
Benzinga · 09/04 14:06
BUZZ-U.S. STOCKS ON THE MOVE-PagerDuty, AMD, Athira Pharma
Reuters · 09/04 13:19
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Zscaler, Dollar Tree
Reuters · 09/04 12:00
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Benzinga · 09/04 10:39
Shuttle Pharmaceuticals Granted U.S. Patent #12077515 For Selective Histone Deacetylase Inhibitors To Treat Human Diseases
Benzinga · 09/03 19:47
Weekly Report: what happened at SHPH last week (0826-0830)?
Weekly Report · 09/02 11:39
SHUTTLE PHARMA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Reuters · 08/28 13:00
Shuttle pharma receives notice of Nasdaq non-compliance
Seeking Alpha · 08/26 20:19
SHUTTLE PHARMA RECEIVES NOTICE OF NASDAQ NON-COMPLIANCE WITH LISTING RULE 5250(C)(1)
Reuters · 08/26 20:10
More
Webull provides a variety of real-time SHPH stock news. You can receive the latest news about SHUTTLE PHARMACTCLS HLDGS INC through multiple platforms. This information may help you make smarter investment decisions.
About SHPH
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.